Research ExplorerPublicationsPDGFB, a new candidate plasma biomarker for venous thromboem...

PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study

Standard

PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. / Bruzelius, Maria; Iglesias, Maria Jesus; Hong, Mun-Gwan; Sanchez-Rivera, Laura; Gyorgy, Beata; Souto, Juan Carlos; Frånberg, Mattias; Fredolini, Claudia; Strawbridge, Rona J; Holmström, Margareta; Hamsten, Anders; Uhlén, Mathias; Silveira, Angela; Soria, Jose Manuel; Smadja, David M; Butler, Lynn M; Schwenk, Jochen M; Morange, Pierre-Emmanuel; Trégouët, David-Alexandre; Odeberg, Jacob.

In: BLOOD, Vol. 128, No. 23, 08.12.2016, p. e59-e66.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bruzelius, M, Iglesias, MJ, Hong, M-G, Sanchez-Rivera, L, Gyorgy, B, Souto, JC, Frånberg, M, Fredolini, C, Strawbridge, RJ, Holmström, M, Hamsten, A, Uhlén, M, Silveira, A, Soria, JM, Smadja, DM, Butler, LM, Schwenk, JM, Morange, P-E, Trégouët, D-A & Odeberg, J 2016, 'PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study', BLOOD, vol. 128, no. 23, pp. e59-e66. https://doi.org/10.1182/blood-2016-05-711846

APA

Bruzelius, M., Iglesias, M. J., Hong, M-G., Sanchez-Rivera, L., Gyorgy, B., Souto, J. C., Frånberg, M., Fredolini, C., Strawbridge, R. J., Holmström, M., Hamsten, A., Uhlén, M., Silveira, A., Soria, J. M., Smadja, D. M., Butler, L. M., Schwenk, J. M., Morange, P-E., Trégouët, D-A., & Odeberg, J. (2016). PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. BLOOD, 128(23), e59-e66. https://doi.org/10.1182/blood-2016-05-711846

Vancouver

Bruzelius M, Iglesias MJ, Hong M-G, Sanchez-Rivera L, Gyorgy B, Souto JC et al. PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. BLOOD. 2016 Dec 8;128(23):e59-e66. https://doi.org/10.1182/blood-2016-05-711846

Bibtex

@article{bd6980d4e5de4a8f9382aa446010c778,
title = "PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study",
abstract = "There is a clear clinical need for high specificity plasma biomarkers for predicting risk of venous thromboembolism (VTE), but thus far such markers have remained elusive. Utilising affinity reagents from the human protein atlas (HPA) project and multiplexed immuoassays we extensively analysed plasma samples from two individual cohorts to identify candidate protein markers associated with VTE risk. We screened plasma samples from 88 VTE cases and 85 matched controls, collected as part of the Swedish 'Venous Thromboembolism Biomarker Study' (VEBIOS), using suspension bead arrays composed of 755 antibodies targeting 408 candidate proteins. We identified significant associations between VTE occurrence and plasma levels of HIVEP1, VWF, GPX3 and PDGFB. For replication we profiled plasma samples of 580 cases and 589 controls from the French FARIVE study. This confirmed the association of VWF and PDGFB with VTE after correction for multiple testing, whilst only weak trends were observed for HIVEP1 and GPX3. Whilst plasma levels of VWF and PDGFB correlated modestly (ρ ~0.30) with each other, they were independently associated with VTE risk in a joint model in FARIVE (VWF p < 0.001; PDGFB p = 0.002). PDGFB was verified as the target of the capture antibody by immunocapture mass spectrometry (IC-MS) and sandwich ELISA. In conclusion, we demonstrate that high-throughput affinity plasma proteomic profiling is a valuable research strategy to identify potential candidate biomarkers for thrombosis related disorders, and our study suggests a novel association of PDGFB plasma levels with VTE.",
author = "Maria Bruzelius and Iglesias, {Maria Jesus} and Mun-Gwan Hong and Laura Sanchez-Rivera and Beata Gyorgy and Souto, {Juan Carlos} and Mattias Fr{\aa}nberg and Claudia Fredolini and Strawbridge, {Rona J} and Margareta Holmstr{\"o}m and Anders Hamsten and Mathias Uhl{\'e}n and Angela Silveira and Soria, {Jose Manuel} and Smadja, {David M} and Butler, {Lynn M} and Schwenk, {Jochen M} and Pierre-Emmanuel Morange and David-Alexandre Tr{\'e}gou{\"e}t and Jacob Odeberg",
note = "Copyright {\textcopyright} 2016 American Society of Hematology.",
year = "2016",
month = dec,
day = "8",
doi = "10.1182/blood-2016-05-711846",
language = "English",
volume = "128",
pages = "e59--e66",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

RIS

TY - JOUR

T1 - PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study

AU - Bruzelius, Maria

AU - Iglesias, Maria Jesus

AU - Hong, Mun-Gwan

AU - Sanchez-Rivera, Laura

AU - Gyorgy, Beata

AU - Souto, Juan Carlos

AU - Frånberg, Mattias

AU - Fredolini, Claudia

AU - Strawbridge, Rona J

AU - Holmström, Margareta

AU - Hamsten, Anders

AU - Uhlén, Mathias

AU - Silveira, Angela

AU - Soria, Jose Manuel

AU - Smadja, David M

AU - Butler, Lynn M

AU - Schwenk, Jochen M

AU - Morange, Pierre-Emmanuel

AU - Trégouët, David-Alexandre

AU - Odeberg, Jacob

N1 - Copyright © 2016 American Society of Hematology.

PY - 2016/12/8

Y1 - 2016/12/8

N2 - There is a clear clinical need for high specificity plasma biomarkers for predicting risk of venous thromboembolism (VTE), but thus far such markers have remained elusive. Utilising affinity reagents from the human protein atlas (HPA) project and multiplexed immuoassays we extensively analysed plasma samples from two individual cohorts to identify candidate protein markers associated with VTE risk. We screened plasma samples from 88 VTE cases and 85 matched controls, collected as part of the Swedish 'Venous Thromboembolism Biomarker Study' (VEBIOS), using suspension bead arrays composed of 755 antibodies targeting 408 candidate proteins. We identified significant associations between VTE occurrence and plasma levels of HIVEP1, VWF, GPX3 and PDGFB. For replication we profiled plasma samples of 580 cases and 589 controls from the French FARIVE study. This confirmed the association of VWF and PDGFB with VTE after correction for multiple testing, whilst only weak trends were observed for HIVEP1 and GPX3. Whilst plasma levels of VWF and PDGFB correlated modestly (ρ ~0.30) with each other, they were independently associated with VTE risk in a joint model in FARIVE (VWF p < 0.001; PDGFB p = 0.002). PDGFB was verified as the target of the capture antibody by immunocapture mass spectrometry (IC-MS) and sandwich ELISA. In conclusion, we demonstrate that high-throughput affinity plasma proteomic profiling is a valuable research strategy to identify potential candidate biomarkers for thrombosis related disorders, and our study suggests a novel association of PDGFB plasma levels with VTE.

AB - There is a clear clinical need for high specificity plasma biomarkers for predicting risk of venous thromboembolism (VTE), but thus far such markers have remained elusive. Utilising affinity reagents from the human protein atlas (HPA) project and multiplexed immuoassays we extensively analysed plasma samples from two individual cohorts to identify candidate protein markers associated with VTE risk. We screened plasma samples from 88 VTE cases and 85 matched controls, collected as part of the Swedish 'Venous Thromboembolism Biomarker Study' (VEBIOS), using suspension bead arrays composed of 755 antibodies targeting 408 candidate proteins. We identified significant associations between VTE occurrence and plasma levels of HIVEP1, VWF, GPX3 and PDGFB. For replication we profiled plasma samples of 580 cases and 589 controls from the French FARIVE study. This confirmed the association of VWF and PDGFB with VTE after correction for multiple testing, whilst only weak trends were observed for HIVEP1 and GPX3. Whilst plasma levels of VWF and PDGFB correlated modestly (ρ ~0.30) with each other, they were independently associated with VTE risk in a joint model in FARIVE (VWF p < 0.001; PDGFB p = 0.002). PDGFB was verified as the target of the capture antibody by immunocapture mass spectrometry (IC-MS) and sandwich ELISA. In conclusion, we demonstrate that high-throughput affinity plasma proteomic profiling is a valuable research strategy to identify potential candidate biomarkers for thrombosis related disorders, and our study suggests a novel association of PDGFB plasma levels with VTE.

U2 - 10.1182/blood-2016-05-711846

DO - 10.1182/blood-2016-05-711846

M3 - SCORING: Journal article

C2 - 27742707

VL - 128

SP - e59-e66

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 23

ER -